About R&D
The Company’s core assets are natural product classes and their synthetic analogues comprising a product platform with multiple partnering and development opportunities.
The Company has exclusive access to the natural product class of the tubulysins discovered by Prof. Höfle and to next generation epothilones, a highly promising new drug class for the treatment of cancer.
Natural and synthetic derivatives of both compound classes exhibit an extremely potent biological activity profile against tubulin and are very useful for novel therapeutic approaches in oncology.
Especially the ability to conjugate the most potent compounds with many delivery technologies or targeting principles offers strong development opportunities towards more efficacious and safer products.
A partnering strategy is pursued for the tubulysin and epothilone projects to fully exploit their potential.
R&D News
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010